Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
RESEARCH TOOLSreports
PRME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.12 - $8.58
Previous CloseN/A
Volume144.88K
Average Volume (3M)1.07M
Market Cap
$289.21M
Enterprise Value$329.21M
Total Cash (Recent Filing)$94.16M
Total Debt (Recent Filing)$43.79M
Price to Earnings (P/E)―
Beta2.94
Next Earnings
May 09, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding131,160,840
10 Day Avg. Volume1,118,944
30 Day Avg. Volume1,072,853
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)96.95
Price to Cash Flow (P/CF)4.50
P/FCF Ratio4.50
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit110.36
Enterprise Value/Ebitda-1.68
Forecast
1Y Price Target
$11.25Price Target Upside387.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Prime Medicine, Inc. News
PremiumCompany Announcements
Prime Medicine Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Prime Medicine Advances Gene Editing and Trials
---
Bulls Say, Bears Say
Bulls Say
Strategic CollaborationsPrime Medicine received $110 million upfront from a strategic research collaboration and license agreement with Bristol Myers Squibb, with potential for more than $3.5 billion in milestone payments.
Technological AdvancementsPrime's technology avoids the DNA double strand breaks (unlike CRISPR) and doubles the targetable nucleotide edits (vs base editing companies like BEAM).
Bears Say
Financial PerformancePrime Medicine reported a net loss of $1.65 per share for 2024, which was higher than the consensus estimates.
---
Ownership Overview
42.74% Insiders
8.18% Mutual Funds
0.34% Other Institutional Investors
39.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $2.12 and its highest was $8.58 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $289.21M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is May 09, 2025 which is in 63 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Feb 28, 2025. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.041.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. does not currently pay dividends.
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.31.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 131,160,840 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went up 4.132%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
---
Prime Medicine, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.25 (387.01% Upside)
$11.25 (387.01% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.35%
12-Months-Change
Fundamentals
Return on Equity
-136.88%
Trailing 12-Months
Asset Growth
54.67%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs.
---
PRME Stock 12 Month Forecast
Average Price Target
$11.25
▲(387.01% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering PRME
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-39.06%
reiterated a buy rating 4 days ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -39.06% per trade.
---